WO2010013494A1 - 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用 - Google Patents

軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用 Download PDF

Info

Publication number
WO2010013494A1
WO2010013494A1 PCT/JP2009/003661 JP2009003661W WO2010013494A1 WO 2010013494 A1 WO2010013494 A1 WO 2010013494A1 JP 2009003661 W JP2009003661 W JP 2009003661W WO 2010013494 A1 WO2010013494 A1 WO 2010013494A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
area
incapable
preparation
transported
Prior art date
Application number
PCT/JP2009/003661
Other languages
English (en)
French (fr)
Inventor
赤池紀生
加藤啓子
原川哲博
鳥居恭司
永野礼隆
奥田祥士
中平伸二
後藤剛孝
銀永明弘
Original Assignee
財団法人化学及血清療法研究所
学校法人銀杏学園熊本保健科学大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 財団法人化学及血清療法研究所, 学校法人銀杏学園熊本保健科学大学 filed Critical 財団法人化学及血清療法研究所
Priority to JP2010522631A priority Critical patent/JPWO2010013494A1/ja
Publication of WO2010013494A1 publication Critical patent/WO2010013494A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

　非投与部位での副作用のないボツリヌス毒素製剤を提供するために、投与部位以外の部位において軸索輸送に伴う副作用を示さないことを特徴とするＨＡ蛋白質非産生性のボツリヌス菌に由来する分子量１５０ｋＤａの神経毒素を主成分として含有する医薬組成物を用いる。上記ボツリヌス神経毒素は、Ａ１型ボツリヌス菌由来神経毒素と比較して、神経軸索を介して非投与部位へ輸送されないため、体重１ｋｇあたり１５Ｕより多く２５Ｕ以下まで大量投与可能となる。
PCT/JP2009/003661 2008-07-31 2009-07-31 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用 WO2010013494A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010522631A JPWO2010013494A1 (ja) 2008-07-31 2009-07-31 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008199068 2008-07-31
JP2008-199068 2008-07-31

Publications (1)

Publication Number Publication Date
WO2010013494A1 true WO2010013494A1 (ja) 2010-02-04

Family

ID=41610204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/003661 WO2010013494A1 (ja) 2008-07-31 2009-07-31 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用

Country Status (2)

Country Link
JP (1) JPWO2010013494A1 (ja)
WO (1) WO2010013494A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015020957A (ja) * 2013-07-17 2015-02-02 国立大学法人徳島大学 筋緊張亢進改善薬
EP2952205A1 (en) * 2014-06-06 2015-12-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
JP2020511428A (ja) * 2017-03-24 2020-04-16 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 唾液腺炎の治療におけるボツリヌス神経毒素の改善された使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013370A1 (en) * 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
WO2006013357A1 (en) * 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
WO2007085728A2 (fr) * 2006-01-27 2007-08-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Composition comprenant plusieurs toxines botuliques
WO2008050866A1 (en) * 2006-10-27 2008-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013370A1 (en) * 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
WO2006013357A1 (en) * 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
WO2007085728A2 (fr) * 2006-01-27 2007-08-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Composition comprenant plusieurs toxines botuliques
WO2008050866A1 (en) * 2006-10-27 2008-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KEIJI OGUMA: "Botulinus Dokuso no Idenshi Oyobi Kozo to Kino ni Kansuru Kenkyu", JAPANESE JOURNAL OF BACTERIOLOGY, vol. 60, no. 4, 2005, pages 521 - 530 *
MITSUHIKO YOKOYAMA ET AL.: "Kairyogata Botulinus Dokuso o Mochiita Translational Research", THE NISHINIHON JOURNAL OF UROLOGY, vol. 68, no. 6, 2006, pages 234 - 238 *
RYUJI KAJI: "Botulinus Dokuso Chiryo no Kongo no Tenbo", THE JOURNAL OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE, vol. 95, no. 9, 2006, pages 1895 - 1899 *
TOYOHIKO WATANABE ET AL.: "Hinyokika no Saizensen Shitteokitai Hinyokika no Atarashii Chiryo to Care no Yoten Kakatsudo Boko (OAB) ni Taisuru Chiryo no Saizensen Botulinus Dokuso Bokohekinai Chunyu Ryoho", UROLOGICAL NURSING, vol. 13, no. 7, 10 July 2008 (2008-07-10), pages 693 - 695 *
YONEDA S. ET AL.: "Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 508, no. 1-3, 2005, pages 223 - 229 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015020957A (ja) * 2013-07-17 2015-02-02 国立大学法人徳島大学 筋緊張亢進改善薬
EP2952205A1 (en) * 2014-06-06 2015-12-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
CN106456709A (zh) * 2014-06-06 2017-02-22 伽利特·克莱纳-菲斯曼 用于治疗伸展过度的肉毒杆菌毒素
JP2017516865A (ja) * 2014-06-06 2017-06-22 クレイナー−フィスマン, ガリットKLEINER−FISMAN, Galit パラトニアの治療における使用のためのボツリヌス毒素
JP2020511428A (ja) * 2017-03-24 2020-04-16 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 唾液腺炎の治療におけるボツリヌス神経毒素の改善された使用
JP7007392B2 (ja) 2017-03-24 2022-01-24 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 唾液腺炎の治療におけるボツリヌス神経毒素の改善された使用
US11529398B2 (en) 2017-03-24 2022-12-20 Merz Pharma Gmbh & Co. Kgaa Use of botulinum neurotoxin in the treatment of sialorrhea

Also Published As

Publication number Publication date
JPWO2010013494A1 (ja) 2012-01-05

Similar Documents

Publication Publication Date Title
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
JP2018531984A5 (ja)
WO2011154126A3 (en) Skin antiaging treatment
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
WO2010100200A3 (en) Lyophilised antibody formulation
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
RU2018119765A (ru) Инъекционные препараты на основе ботулотоксина и способы их применения, обеспечивающие длительное терапевтическое и косметического действие
WO2010013495A1 (ja) 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
WO2009125423A3 (en) Compositions useful for the treatment of diabetes and other chronic disorder
WO2012065072A3 (en) IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
WO2012076670A3 (en) Antibody formulation
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
WO2011060206A3 (en) Material and methods for treating or preventing her-3 associated diseases
WO2008058547A3 (en) Alpha-lactalbumin composition
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ702801A (en) Treatment of sanfilippo syndrome type b
WO2007109184A3 (en) Anti-cancer activity augmentation compounds and formulations and methods of use thereof
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
WO2012138570A3 (en) Modulating bacterial mam polypeptides in pathogenic disease
WO2007087154A3 (en) Methods for enhancing therapeutic effects of a neurotoxin
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09802739

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2010522631

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09802739

Country of ref document: EP

Kind code of ref document: A1